Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SR58611A vs placebo vs paroxetine in generalized anxiety disorder
2005-003181-41Phase 3Completed
- Sponsor
- Sanofi
- Start
- Dec 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of amibegron in generalized anxiety disorder (GAD) (3 arms), sponsored by Sanofi. Primary endpoint: Primary efficacy at V7 (Day 56). Started Dec 2005; status: completed.
02
Drugs
amibegron
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on 2005-003181-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003181-41.